Clinical trials: Lou Gehrig Disease
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Virtual Peer-to-peer Support Programme for Carers of MND
Background/scope There is growing recognition that family caregiving is a serious public health issue requiring supportive interventions.
- Trial name
- NCT04695210
- Testing
- Virtual peer-to-peer support
- Where
- 25 sites in United Kingdom
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- King's College London
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Rehabilitation in SOD1 ALS Treated With Tofersen
The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- NCT05725759
- Testing
- Rehabilitation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Amyotrophic Lateral Sclerosis
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00072709
- Testing
- TCH346
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Intermediate-Sized Expanded Access Study
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
- Trial name
- NCT05597436
- Testing
- Trehalose
- Where
- 21 sites in United States
- Sponsor
- Seelos Therapeutics, Inc.
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Tetraplegia
NeuroCognitive Communicator: Safety Study
Individuals suffering from tetraplegia as a result of cervical spinal cord injury, brainstem stroke, or amyotrophic lateral sclerosis (ALS) cannot independently perform tasks of daily living.
- Trial name
- NCC-1701 (NCT03100110)
- Testing
- NeuroCognitive Communicator
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ottawa Hospital Research Institute
ALS, Amyotrophic Lateral Sclerosis
Speech Analysis in ALS Patients
The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year.
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
- Trial name
- NCT03868345
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Barrow Neurological Institute
Amyotrophic Lateral Sclerosis
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by…
- Trial name
- JETALS (NCT03548311)
- Testing
- methylcobalamin, saline solution
- Where
- 16 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Eisai Co., Ltd.
ALS (Amyotrophic Lateral Sclerosis)
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
- Trial name
- KOANEWA (NCT07401121)
- Testing
- AAV9 Gene therapy
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Celosia Therapeutics Pty Ltd
Pseudobulbar Affect (PBA)
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate [AVP-923-30] or 20…
- Trial name
- STAR (NCT00573443)
- Testing
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
- Where
- 62 sites in United States, Argentina and 1 more
- Volunteers
- 326 people
- Sponsor
- Avanir Pharmaceuticals
Motor Neuron Disease
EncoreAnywhere Use in Motor Neurone Disease
Motor neurone disease is a progressive incurable disease causing weakness and paralysis of muscles. Respiratory failure is the most common cause of death in motor neurone disease.
- Trial name
- NCT03154450
- Testing
- EncoreAnywhere with data available to review, EncoreAnywhere with no data available to review
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy
- Trial name
- NCT06315608
- Testing
- MRG-001
- Volunteers
- 10 people
- Sponsor
- MedRegen LLC
Sporadic Amyotrophic Lateral Sclerosis
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown.
- Trial name
- Fibro-ALS (NCT02969759)
- Testing
- Skin Biopsy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Amyotrophic Lateral Sclerosis
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.
- Trial name
- NCT06215755
- Testing
- VRG50635
- Where
- 7 sites in Belgium, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- Verge Genomics
Amyotrophic Lateral Sclerosis
Analysis of Human ALS Tissues and Registry of ALS Patients
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain.
- Trial name
- NCT05067179
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
Amyotrophic Lateral Sclerosis
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04326283
- Testing
- Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg)
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- Genuv Inc.
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Telemonitoring in NIV MND (OptNIVent)
This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group.
- Trial name
- OptNIVent (NCT05299372)
- Testing
- Telemonitoring via Careportal®
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Amyotrophic Lateral Sclerosis
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.
- Trial name
- NCT02039401
- Testing
- VM202
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Helixmith Co., Ltd.
Familial Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions.
- Trial name
- SOD-1 (NCT01041222)
- Testing
- ISIS 333611
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis, ALS
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive…
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03537807
- Testing
- Riluzole
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Motor Neuron Disease
A Study of Monepantel in Individuals With Motor Neurone Disease
Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden.
- Trial name
- NCT04894240
- Testing
- Monepantel
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Neurizon Therapeutics Limited